N-Acetyl Cysteine (NAC) pour Helicobacter pylori Infection
C Preuves Preuves limitées issues de petites études, mais certains signaux positifs existent.NAC (600-1,200 mg/day) may improve H. pylori eradication rates by disrupting biofilm. Small studies show improved eradication when combined with standard therapy.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dn\u002Dacetyl\u002Dcysteine\u0026condition\u003Dh\u002Dpylori';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
En conclusion
NAC (600-1,200 mg/day) may improve H. pylori eradication rates by disrupting biofilm. Small studies show improved eradication when combined with standard therapy.
Key Study Findings
In Vitro
Berberrubine inhibits Helicobacter pylori by inducing oxidative stress and impairing membrane integrity.
Dose: MIC 11 μg/mL
vs: None
Outcome: anti-Helicobacter pylori activity
Effet: None
None
Population: None
Other
Correction to "N-Acetylcysteine Reduces ROS-Mediated Oxidative DNA Damage and PI3K/Akt Pathway Activation Induced by Helicobacter …
Dose: None
vs: None
Outcome: None
Effet: None
None
Population: Published erratum (correction notice)
Review
Posttranslational modifications in Helicobacter pylori-associated gastric pathogenesis: Bridging inflammation and carcinogenesis.
Dose: None
vs: None
Outcome: None
Effet: None
None
Population: None
Other
Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in Augmented Therapy.
Dose: None
vs: None
Outcome: Cancer outcomes
Effet: None
None
Population: Cancer patients
In Vitro
Helicobacter pylori infection selectively attenuates endothelial function in male mice via exosomes-mediated ROS production.
Dose: None
vs: None
Outcome: choline levels/cognition
Effet: None
None
Population: Mice
Other
α-Lipoic Acid Inhibits Apoptosis by Suppressing the Loss of Ku Proteins in Helicobacter pylori-Infected Human …
Dose: None
vs: None
Outcome: None
Effet: None
None
Population: None
Key Statistics
3
Études
250
Participants
↑
Positive
C
Note
Referenced Papers
mLife
2026
Biochimica et biophysica …
2025
1 citations
Oxidative medicine and …
2025
Pharmaceutics
2024
8 citations
Frontiers in cellular …
2023
7 citations
Frontiers in cardiovascular …
2022
27 citations
Nutrients
2022
11 citations
Microbial drug resistance …
2020
34 citations
Therapeutic advances in …
2020
7 citations
Synthesis of Fucose Derivatives with Thiol Motifs towards Suicide Inhibition of Helicobacter pylori.
Other
Molecules (Basel, Switzerland)
2020
Expert review of …
2019
85 citations
The Cochrane database …
2019
21 citations
Oxidative medicine and …
2018
93 citations
The effect of antioxidants on Helicobacter pylori eradication: A systematic review with meta-analysis.
Meta-Analysis
Helicobacter
2018
18 citations
N-acetylcysteine prevents the development of gastritis induced by Helicobacter pylori infection.
Other
Journal of microbiology …
2017
16 citations
Cell host & …
2016
101 citations
Helicobacter
2016
60 citations
Nutrition research (New …
2016
25 citations
Molecular carcinogenesis
2016
18 citations
Gut and liver
2016
17 citations
Pathogens and disease
2015
64 citations
World journal of …
2015
21 citations
Journal of cancer …
2013
10 citations
Alimentary pharmacology & …
2012
104 citations
Clinical and experimental …
2012
1 citations
Journal of clinical …
2011
34 citations
Clinical gastroenterology and …
2010
103 citations
Pharmaceutical biology
2010
16 citations
Probiotics and antimicrobial …
2010
9 citations
American family physician
2009
Helicobacter
2007
130 citations
World journal of …
2007
77 citations
Journal of agricultural …
2007
44 citations
American journal of …
2007
11 citations
Digestive diseases and …
2004
53 citations
Digestive diseases and …
2004
4 citations
Digestive diseases and …
2003
69 citations
Annals of the …
2002
30 citations
Journal of environmental …
2002
Pharmacological research
2001
25 citations
Schweizerische medizinische Wochenschrift
1994
22 citations
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Posologies couramment utilisées
- general:
- 600-1,200 mg/day in divided doses
- hpyloriadjunct:
- 600 mg twice daily alongside standard triple therapy
- antioxidantsupport:
- 600-900 mg/day
Limite supérieure : Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings
Posologies étudiées dans la recherche
| Posologie | Durée | Effet | N |
|---|---|---|---|
| MIC 11 μg/mL | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Negative | -- |
| None | -- | Positive | -- |
Moment optimal de prise : With or without food; divide doses throughout the day
Safety & Side Effects
Effets indésirables signalés
- ⚠ Nausea and vomiting (most common, especially at higher doses)
- ⚠ Diarrhea
- ⚠ Unpleasant sulfur taste/odor
- ⚠ Headache
Interactions connues
- ● Nitroglycerin (NAC may enhance vasodilatory effects; risk of hypotension)
- ● Activated charcoal (may reduce NAC absorption)
- ● Anticoagulants (NAC may have mild antiplatelet effects)
- ● ACE inhibitors (additive hypotensive effect with nitroglycerin combination)
Apport maximal tolérable : Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings
Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.
Frequently Asked Questions
Does N-Acetyl Cysteine (NAC) help with Helicobacter pylori Infection?
Based on 3 studies with 250 participants, there is limited but promising evidence that N-Acetyl Cysteine (NAC) may support Helicobacter pylori Infection management. Our evidence grade is C (Some Evidence).
How much N-Acetyl Cysteine (NAC) should I take for Helicobacter pylori Infection?
Studies have used various dosages. A commonly studied range is 600-1,200 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of N-Acetyl Cysteine (NAC)?
Reported side effects may include Nausea and vomiting (most common, especially at higher doses), Diarrhea, Unpleasant sulfur taste/odor, Headache. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for N-Acetyl Cysteine (NAC) and Helicobacter pylori Infection?
We rate the evidence as Grade C (Some Evidence). This rating is based on 3 peer-reviewed studies with 250 total participants. The overall direction of effect is positive.
Related Evidence
Autres ingrédients pour Helicobacter pylori Infection
N-Acetyl Cysteine (NAC) pour d'autres pathologies
References
- [1] Minzhi Jiang et al.. mLife. 2026. Berberrubine inhibits Helicobacter pylori by inducing oxidative stress and impairing membrane integrity. doi:10.1002/mlf2.70061 PubMed
- [2] Wei Li et al.. Biochim Biophys Acta Rev Cancer. 2025. Posttranslational modifications in Helicobacter pylori-associated gastric pathogenesis: Bridging inflammation and carcinogenesis. doi:10.1016/j.bbcan.2025.189492 PubMed
- [3] . Oxid Med Cell Longev. 2025. Correction to "N-Acetylcysteine Reduces ROS-Mediated Oxidative DNA Damage and PI3K/Akt Pathway Activation Induced by Helicobacter pylori Infection". doi:10.1155/omcl/9794537 PubMed
- [4] Muhammad Irfan Alam et al.. Pharmaceutics. 2024. Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in Augmented Therapy. doi:10.3390/pharmaceutics16091123 PubMed
- [5] Linfang Zhang et al.. Front Cell Infect Microbiol. 2023. Helicobacter pylori infection selectively attenuates endothelial function in male mice via exosomes-mediated ROS production. doi:10.3389/fcimb.2023.1142387 PubMed
- [6] Xiujuan Xia et al.. Front Cardiovasc Med. 2022. CagA+ Helicobacter pylori, Not CagA- Helicobacter pylori, Infection Impairs Endothelial Function Through Exosomes-Mediated ROS Formation. doi:10.3389/fcvm.2022.881372 PubMed
- [7] Dayong Park et al.. Nutrients. 2022. α-Lipoic Acid Inhibits Apoptosis by Suppressing the Loss of Ku Proteins in Helicobacter pylori-Infected Human Gastric Epithelial Cells. doi:10.3390/nu14153206 PubMed
- [8] Yuanna Shen et al.. Microb Drug Resist. 2020. Activity of Sodium Lauryl Sulfate, Rhamnolipids, and N-Acetylcysteine Against Biofilms of Five Common Pathogens. doi:10.1089/mdr.2018.0385 PubMed
- [9] Chieh-Chang Chen et al.. Therap Adv Gastroenterol. 2020. Comparison of the effect of clarithromycin triple therapy with or without N-acetylcysteine in the eradication of Helicobacter pylori: a randomized … doi:10.1177/1756284820927306 PubMed
- [10] Mark Reihill et al.. Molecules. 2020. Synthesis of Fucose Derivatives with Thiol Motifs towards Suicide Inhibition of Helicobacter pylori. doi:10.3390/molecules25184281 PubMed
- [11] Lyudmila Boyanova et al.. Expert Rev Clin Pharmacol. 2019. Multidrug resistance in Helicobacter pylori: current state and future directions. doi:10.1080/17512433.2019.1654858 PubMed
- [12] Luís Eduardo S Fontes et al.. Cochrane Database Syst Rev. 2019. N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication. doi:10.1002/14651858.CD012357.pub2 PubMed
- [13] Chuan Xie et al.. Oxid Med Cell Longev. 2018. N-Acetylcysteine Reduces ROS-Mediated Oxidative DNA Damage and PI3K/Akt Pathway Activation Induced by Helicobacter pylori Infection. doi:10.1155/2018/1874985 PubMed
- [14] Yao-Bin Yang-Ou et al.. Helicobacter. 2018. The effect of antioxidants on Helicobacter pylori eradication: A systematic review with meta-analysis. doi:10.1111/hel.12535 PubMed
- [15] Sungil Jang et al.. J Microbiol. 2017. N-acetylcysteine prevents the development of gastritis induced by Helicobacter pylori infection. doi:10.1007/s12275-017-7089-9 PubMed
- [16] Kristof Moonens et al.. Cell Host Microbe. 2016. Structural Insights into Polymorphic ABO Glycan Binding by Helicobacter pylori. doi:10.1016/j.chom.2015.12.004 PubMed
- [17] Juan-Yu Piao et al.. Helicobacter. 2016. Helicobacter pylori Activates IL-6-STAT3 Signaling in Human Gastric Cancer Cells: Potential Roles for Reactive Oxygen Species. doi:10.1111/hel.12298 PubMed
- [18] Aryoung Kim et al.. Nutr Res. 2016. Supplementation with Angelica keiskei inhibits expression of inflammatory mediators in the gastric mucosa of Helicobacter pylori-infected mice. doi:10.1016/j.nutres.2015.12.017 PubMed
- [19] Hoang-Kieu-Chi Ngo et al.. Mol Carcinog. 2016. Helicobacter pylori induces Snail expression through ROS-mediated activation of Erk and inactivation of GSK-3β in human gastric cancer cells. doi:10.1002/mc.22464 PubMed
- [20] Hyuk Yoon et al.. Gut Liver. 2016. Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial. doi:10.5009/gnl15048 PubMed
- [21] Xiang Li et al.. Pathog Dis. 2015. Helicobacter pylori induces IL-1β and IL-18 production in human monocytic cell line through activation of NLRP3 inflammasome via ROS signaling … doi:10.1093/femspd/ftu024 PubMed
- [22] Fatih Ermis et al.. World J Methodol. 2015. Current Helicobacter pylori treatment in 2014. doi:10.5662/wjm.v5.i2.101 PubMed
- [23] Minkyung Bae et al.. J Cancer Prev. 2013. Oxidative DNA Damage Response in Helicobacter pylori-Infected Mongolian Gerbils. doi:10.15430/jcp.2013.18.3.271 PubMed
- [24] G Cammarota et al.. Aliment Pharmacol Ther. 2012. Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. doi:10.1111/j.1365-2036.2012.05165.x PubMed
- [25] Riccardo Urgesi et al.. Clin Exp Gastroenterol. 2012. Update on triple therapy for eradication of Helicobacter pylori: current status of the art. doi:10.2147/CEG.S25416 PubMed
- [26] Kian Makipour et al.. J Clin Gastroenterol. 2011. The potential role of N-acetylcysteine for the treatment of Helicobacter pylori. doi:10.1097/MCG.0b013e31822be4d6 PubMed
- [27] Giovanni Cammarota et al.. Clin Gastroenterol Hepatol. 2010. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. doi:10.1016/j.cgh.2010.05.006 PubMed
- [28] Thomas Sawidis et al.. Pharm Biol. 2010. Chios mastic, a natural supplement for zinc to enhance male sexuality and prostate function. doi:10.3109/13880200903029399 PubMed
- [29] Luc De Vuyst et al.. Probiotics Antimicrob Proteins. 2010. Peptide Extracts from Cultures of Certain Lactobacilli Inhibit Helicobacter pylori. doi:10.1007/s12602-009-9029-4 PubMed
- [30] Paul J Millea. Am Fam Physician. 2009. N-acetylcysteine: multiple clinical applications. PubMed
- [31] Francesco Di Mario et al.. Helicobacter. 2007. A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? doi:10.1111/j.1523-5378.2007.00497.x PubMed
- [32] Chun-Chao Chang et al.. World J Gastroenterol. 2007. Premedication with pronase or N-acetylcysteine improves visibility during gastroendoscopy: an endoscopist-blinded, prospective, randomized study. doi:10.3748/wjg.v13.i3.444 PubMed
- [33] Gabriel A Agbor et al.. J Agric Food Chem. 2007. Effect of selenium- and glutathione-enriched yeast supplementation on a combined atherosclerosis and diabetes hamster model. doi:10.1021/jf0711901 PubMed
- [34] Breda M Walsh et al.. Am J Physiol Cell Physiol. 2007. Thiol-oxidant monochloramine mobilizes intracellular Ca2+ in parietal cells of rabbit gastric glands. doi:10.1152/ajpcell.00189.2006 PubMed
- [35] Hien Quoc Huynh et al.. Dig Dis Sci. 2004. N-acetylcysteine, a novel treatment for Helicobacter pylori infection. doi:10.1007/s10620-004-9583-2 PubMed
- [36] Geoffrey M Matthews et al.. Dig Dis Sci. 2004. Cellular mucosal defense is attenuated with chronicity of Helicobacter pylori infection. doi:10.1023/b:ddas.0000037796.64430.f6 PubMed
- [37] Sang Hui Chu et al.. Dig Dis Sci. 2003. Role of NF-kappaB and AP-1 on Helicobater pylori-induced IL-8 expression in AGS cells. doi:10.1023/a:1021963007225 PubMed
- [38] Jeong Yeon Seo et al.. Ann N Y Acad Sci. 2002. Transcriptional regulation by thiol compounds in Helicobacter pylori-induced interleukin-8 production in human gastric epithelial cells. doi:10.1111/j.1749-6632.2002.tb04697.x PubMed
- [39] Hyeyoung Kim et al.. J Environ Pathol Toxicol Oncol. 2002. Oxidant-sensitive transcription factor and cyclooxygenase-2 by Helicobacter pylori stimulation in human gastric cancer cells. PubMed
- [40] W S Hong et al.. Pharmacol Res. 2001. The antioxidant effect of rebamipide on oxygen free radical production by H. pylori-activated human neutrophils: in comparison with N-acetylcysteine, ascorbic … doi:10.1006/phrs.2001.0839 PubMed
- [41] G Zala et al.. Schweiz Med Wochenschr. 1994. [Omeprazole/amoxicillin: improved eradication of Helicobacter pylori in smokers because of N-acetylcysteine]. PubMed
Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.